Approaching clinical proteomics: current state and future fields of application in fluid proteomics
Autor: | Hans-Werner Mewes, Charalampos Aslanidis, Andreas Thiel, Andreas O. H. Gerstner, Joachim Thiery, Rolf Apweiler, Wolfgang Mutter, Christoph Wagener, Jens Hansen, Edmund Maser, Friedrich Lottspeich, Peter Nollau, Andreas Radbruch, Michael J. Taussig, Oswald Wagner, Gregor Rothe, Fredrik Pontén, Thomas Deufel, Michael Neumaier, Stefan Müllner, Gerd Schmitz, Helmut E. Meyer, Marius Ueffing, Wiltrud Verhuven, Knut Reinert, Attila Tárnok, Hans G. Nothwang, Hannes Stockinger, Dennis Hochstrasser, Joël Vandekerckhove, Markus Kubicek, Roland Kellner, G. Valet |
---|---|
Rok vydání: | 2009 |
Předmět: |
Proteomics
Clinical Medicine/*methods/standards/trends FLOW-CYTOMETRIC ASSAYS Standardization 2-DIMENSIONAL GEL-ELECTROPHORESIS Computer science ENHANCED LASER-DESORPTION/IONIZATION Clinical Biochemistry Body Fluids/*chemistry cerebrospinal fluid (CSF) Computational biology PROTEIN-PROTEIN INTERACTIONS Biological variation surface-enhanced laser desorption/ionization (SELDI) Medicine and Health Sciences mass spectrometry (MS) MAGNETIC BEAD SEPARATION ddc:576 BRONCHOALVEOLAR LAVAGE FLUID TRANSITIONAL-CELL CARCINOMA Proteomics/*methods/standards/trends standard operating procedures (SOP) FLIGHT-MASS-SPECTROMETRY [KeyWords Plus] Biochemistry (medical) Proteins/*analysis fluid proteomics Proteins DESORPTION-IONIZATION-TIME General Medicine preanalytical effects Diagnostic strategy Body Fluids clinical proteomics INTRA-INDIVIDUAL VARIATION Spectrometry Mass Matrix-Assisted Laser Desorption-Ionization Proteome Protein microarray Biomarker (medicine) Biological Markers/analysis Sample collection matrix assisted laser desorption/ionization (MALDI) Clinical Medicine Biomarkers |
Zdroj: | Clinical Chemistry and Laboratory Medicine, Vol. 47, No 6 (2009) pp. 724-744 CLINICAL CHEMISTRY AND LABORATORY MEDICINE |
ISSN: | 1437-4331 1434-6621 |
Popis: | The field of clinical proteomics offers opportunities to identify new disease biomarkers in body fluids, cells and tissues. These biomarkers can be used in clinical applications for diagnosis, stratification of patients for specific treatment, or therapy monitoring. New protein array formats and improved spectrometry technologies have brought these analyses to a level with potential for use in clinical diagnostics. The nature of the human body fluid proteome with its large dynamic range of protein concentrations presents problems with quantitation. The extreme complexity of the proteome in body fluids presents enormous challenges and requires the establishment of standard operating procedures for handling of specimens, increasing sensitivity for detection and bioinformatical tools for distribution of proteomic data into the public domain. From studies of in vitro diagnostics, especially in clinical chemistry, it is evident that most errors occur in the preanalytical phase and during implementation of the diagnostic strategy. This is also true for clinical proteomics, and especially for fluid proteomics because of the multiple pretreatment processes. These processes include depletion of high-abundance proteins from plasma or enrichment processes for urine where biological variation or differences in proteolytic activities in the sample along with preanalytical variables such as inter- and intra-assay variability will likely influence the results of proteomics studies. However, before proteomic analysis can be introduced at a broader level into the clinical setting, standardization of the preanalytical phase including patient preparation, sample collection, sample preparation, sample storage, measurement and data analysis needs to be improved. In this review, we discuss the recent technological advances and applications that fulfil the criteria for clinical proteomics, with the focus on fluid proteomics. These advances relate to preanalytical factors, analytical standardization and quality-control measures required for effective implementation into routine laboratory testing in order to generate clinically useful information. With new disease biomarker candidates, it will be crucial to design and perform clinical studies that can identify novel diagnostic strategies based on these techniques, and to validate their impact on clinical decision-making. Clin Chem Lab Med 2009;47:724–44. |
Databáze: | OpenAIRE |
Externí odkaz: |